



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2023 #42

November 17, 2023

INSIDE:

WORD IN WASHINGTON	2
REGULATORY NEWS ...	2
RESEARCH IN BRIEF ...	3
PEOPLE.....	4
MEMBER NEWS.....	4
Deadline Extended for 27 th Awards of Excellence Nominations	5
Call for ABC Council of States Representatives	5
Registration Is Open for 2024 ABC Annual Meeting	5
Save the Date: SMT Journal Club Webinar Set for December 15 th ..	6
GLOBAL NEWS	6
COMPANY NEWS.....	7
CALENDAR.....	8
EQUIPMENT AVAILABLE	9
POSITIONS.....	9

Please Note: The ABC Newsletter will not be published on Friday, Nov. 24th. We will resume publication on Monday Dec. 4th. Thank you for your continued interest.

ABC Responds to ACBTSA Recommendations

America's Blood Centers (ABC) has provided [comments](#) to [recommendations](#) published by the [U.S. Department of Health and Human Services \(HHS\) Advisory Committee on Blood and Tissue Safety and Availability \(ACBTSA\)](#). In the comments, ABC expressed that it is, "extremely supportive of the recommendations of the Committee to address surge capacity for blood and blood products."

Specifically, ABC explained that, "[we] support the Zika payment model but encourages expansion of the model to:

- ensure blood establishments are not collecting blood at risk; and
- establish funding for local public awareness about the need for blood donors."

The comments also noted that while ABC supports federal public awareness campaigns, "we believe the best use of any future federal funding for public awareness for blood donation is best directed locally. [F]unding for local awareness distributed directly to blood centers as part of an Other Transaction Agreement between the U.S. government and ABC during COVID-19 resulted in a 244 percent increase in collections. It is essential that the U.S. government invest in local funding for blood establishments to use in increasing awareness of blood donation, especially among diverse, young, and newly eligible individuals. ABC recommends that the Committee emphasize the need to provide funding for public awareness campaigns at the local level."

Additionally, ABC recommended that the ACBTSA:

- "work with its partners at the U.S. Food and Drug Administration (FDA) to pre-establish additional regulatory flexibility that would be granted in case of short or long-term surge capacity needs to extend the U.S. blood supply without impacting the safety, purity, or potency of blood donations;"
- establish a baseline inventory of blood;
- model unprecedented emergency scenarios; and
- establish funding for a sustained increase in blood inventories.

The full recommendations are [available](#) on the ABC website. Please contact ABC Director of Regulatory Affairs and Public Policy [Justine Coffey, JD, LLM](#), with any questions.

(Source: ABC [Recommendations](#) to ACBTSA, 11/16/23) ♦



WORD IN WASHINGTON

Both the U.S. Senate and House of Representatives have [passed](#) a stopgap spending bill to fund the federal government and avoid a shutdown through January 19th. President Biden signed the bill on November 16th. According to the *Associated Press*, “[t]he measure passed the House and Senate by wide bipartisan margins this week, [and potentially gives] lawmakers more time to sort out [government] spending levels for the current budget year.”

(Source: *Associated Press*, “[Biden signs a bill averting a government shutdown for now, with Israel and Ukraine aid still stalled](#), 11/17/23

A [report](#) in *STAT News* stated that the U.S. Food and Drug Administration, “is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.” The article also explained that the, “overhaul includes a new name: [the] Office of Inspections and Investigations.” *STAT News* also reported that, “[the Centers for Biologics Evaluation and Research (CBER), [is] undoing a reorganization of the Office of Blood Research and Review (OBRR) that was announced as part of its major reorganization last June.”

(Source: *STAT News*, “[FDA’s latest reorganization puts a new emphasis on its investigations](#), 11/15/23) ◆

REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) [published](#) an amendment on November 9th to a rule titled “Medical Devices; Hematology and Pathology Devices; Classification of the Container System for the Processing and Storage of Red Blood Cell Components Under Reduced Oxygen Conditions.” In the rule summary, the agency stated that it is “classifying the container system for the processing and storage of Red Blood Cell components under reduced oxygen conditions into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the classification of the container system for the processing and storage of Red Blood Cell components under reduced oxygen conditions. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices.” FDA explained that it received a request from Hemanext, Inc. for De Novo classification of the Hemanext One and, “determined that the device can be classified into class II with the establishment of special controls. FDA has determined that these special controls, in addition to the general controls, will provide reasonable assurance of the safety and effectiveness of the device...In this final order, FDA is codifying the classification of the device by adding [21 CFR 864.9115](#). We have named the generic type of device container system for the processing and storage of Red Blood Cell components under reduced oxygen conditions, identified as a device intended for medical purposes that is used to process and store Red Blood Cell components and reduce oxygen levels in the storage environment.”

(Source: *Federal Register*, [FDA Rule](#), 11/9/23) ◆



RESEARCH IN BRIEF

International Forum on Donors with Germline Predisposition to Malignancy. A [survey](#) in *Vox Sanguinis* “aim[ed] to capture current patterns of donor selection and deferral for individuals with current, past or germline predisposition to malignancy, to inform evidence-based policy and development of guidelines for these individuals.” The authors noted that there were “12 responses from 12 countries.” Of the responses, “nine allowed donations from individuals with minimally invasive malignancies, all 12 respondents imposed deferral periods on all other solid organ tumor types.” The paper explained that, “no respondents allowed donation of blood components from individuals with active hematological malignancy, under any circumstances...However, most (11/12, 92 percent) allowed donation from some donors with past malignancy depending on tumor type, documentation of cure and/or a minimum amount of time elapsed since cancer treatment...Only two respondents reported existing donor guidelines for individuals with germline predisposition to solid organ malignancy. Within these guidelines, individuals with a high risk of cancer due to family history or following genetic tests, including recipients of prophylactic surgery or on prophylactic medication such as tamoxifen, are accepted as donors. Despite a lack of formal guidelines, all 12 respondents stated they would accept donations from individuals with genetic predisposition to solid organ malignancy.” The authors also noted that, “none of the surveyed blood services had existing donor guidelines for individuals with germline predisposition to hematological malignancy. Despite this, all 12 respondents stated they would accept donations from [these] individuals...Potential donors with active hematological malignancy were perceived by respondents to carry the highest risk from donating blood...Regarding specific risks, the majority of respondents reported concerns regarding exacerbation of donor cytopenias (nine respondents, 75 percent), adverse donor reactions such as injection site bruising or infection (11 respondents, 92 percent), risk to the recipient of acquired red cell and platelet dysfunction (9 respondents, 75 percent) and theoretical risk of cancer transmission (eight respondents, 67 percent)...Overall, there was moderate variation across blood services internationally in the approach to donor selection and product recall for individuals with current, past or germline predisposition to cancer.” The authors concluded that, “the challenge of balancing theoretical donor and recipient risk with demands on providing sufficient national blood supply should be underscored.”

Citation: Baggio, D., Fox, L.C., Wood, E.M., Aditya, R.N., Goldman, M., van den Berg, K., *et al.* “[International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: Summary.](#)” *Vox Sanguinis*. 2023.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2023 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Jed Gorlin

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$420

Send subscription queries to

memberservices@americasblood.org

America’s Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



PEOPLE



Gulf Coast Regional Blood Center has announced the retirement of **Susan Rossmann, MD, PhD** as chief medical officer. During her career at the blood center, she was a vital part of the blood community at both the local and national levels including serving as the primary non-voting industry representative for the U.S. Food and Drug Administration's Blood Products Advisory Committee (BPAC), president of America's Blood Centers (ABC), chair of ABC's Scientific, Medical, and Technical (SMT) Committee, a member of the ABC Working Group for Donor Education and Communication, ABC liaison to the College of American Pathologists' Transfusion Medicine Resource Committee, chair of the Association for the Advancement of Blood & Biotherapies (AABB) Donor History Questionnaire Task Force, and as a volunteer assessor. According to the news release, "Dr. Rossmann began her journey with Gulf Coast Regional Blood Center in 2001 as the Medical Director. In 2004, she made history by becoming the center's first Chief Medical Officer... Before her tenure at Gulf Coast Regional Blood Center, Dr. Rossmann served as head of the blood bank at Texas Children's Hospital. She also held academic appointments at The University of Texas Health Science Center and Baylor College of Medicine. Her dedication to patient care and education has left a lasting mark on the healthcare community." Dr. Rossmann completed her undergraduate studies at Mount Holyoke College and received an MA and PhD in anthropology from the University of Michigan. In 1989, she received her MD from Baylor College of Medicine, where she also completed her residency in anatomic and clinical pathology. She is board certified in both anatomic and clinical pathology and certified in blood banking/transfusion medicine by the American Board of Pathology. Beth Hartwell, MD, chief medical officer at Gulf Coast Regional Blood Center, added in the news release, "Dr. Susan Rossmann's retirement marks the end of an era. Her passion, dedication, and leadership have driven our commitment to ensuring a safe and adequate blood supply for our community. Although she may not have realized it, she has served as a role model and mentor to many, me included. We are immensely grateful for her extraordinary contributions and wish her a well-deserved retirement filled with happiness and new adventures." Gulf Coast Regional Blood Center is encouraging the blood community to join them in "congratulating Dr. Rossmann on her retirement and thanking her for incredible contributions to the medical community and the cause of blood donation and transfusion safety." The organization has prepared a "[Dropbox](#) to collect all the memories for Dr. Rossmann [and is asking individuals] to upload photos that capture beloved memories with Dr. Rossmann. You can also record a video or pen a heartfelt message that will be cherished forever."

(Source: Gulf Coast Regional Blood Center News Release, 11/15/23) 💧

MEMBER NEWS



Carter BloodCare recently recognized 2023 National Blood Donation Hall of Fame inductee [Kirk Hunter](#). The induction event took place on November 9th at Carter BloodCare's headquarters in Bedford, Texas. Mr. Hunter is a transfusion recipient and blood donor advocate. He is one of 12 individuals announced earlier this year as the newest inductees of the [National Blood Donation Hall of Fame](#).

(Source: Carter BloodCare Announcement, 11/9/23) 💧



America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

Deadline Extended for 27th Awards of Excellence Nominations

The deadline to submit [nominations](#) for the 27th Annual America's Blood Centers (ABC) *Awards of Excellence* has been extended to December 5th. This year, awardees will be recognized during the [2024 ABC Annual Meeting](#) and at a reception on Capitol Hill (Tuesday, March 5th), where a celebration of the awardees' achievements will include fellow meeting attendees, members of Congress and their staff, federal agency partners, and more. A full description of the awards is [available](#) to ABC members and all members of ABC are encouraged to submit a [nomination](#). Please contact [us](#) with any questions.

(Source: [MCN 23-094](#), 11/9/23)

Call for ABC Council of States Representatives

ABC recently announced the formation of the Council of States, a first-of-its-kind project that convenes member blood center representatives to conduct state-based advocacy work in a unified manner. Through the Council, ABC seeks interested individuals from member blood centers to identify proactive state-based advocacy priorities, share best practices, and monitor state legislation and regulations. While this effort will not replace the need for state-by-state lobbying activities and strategies, it will mobilize and build on our collective strength and synergies when we work together. Additional information including the charter and sign-up form for the Council are available in [MCN 23-091](#). The deadline to complete the sign-up form is December 1st. Please contact ABC Chief Executive Officer [Kate Fry, MBA, CAE](#) with any questions. The first meeting of the ABC Council of States will take place on March 6th at the [2024 ABC Annual Meeting](#).

(Source: [MCN 23-091](#), 11/2/23)

Registration Is Open for 2024 ABC Annual Meeting

[Registration](#) is open for the ABC [2024 Annual Meeting](#). The meeting will take place March 4th-6th in Arlington, Va. at the Ritz-Carlton in Pentagon City and features several exciting changes, including expanded content offerings and a new format. With a focus on advocacy, leadership, operations, and science and medicine, the program will feature a mix of general and breakout sessions, external speakers and blood center-led case studies, committee and council meetings, networking events, and more. [Awards of Excellence](#) (AoE) winners will be [recognized](#) throughout the Annual Meeting and at a reception on Capitol Hill, where we can celebrate their achievements with fellow meeting attendees, members of Congress and their staff, our federal agency partners, Blood Advocacy Week partners, and more. The call for AoE nominations is [open](#). Secure your [room](#) today to take advantage of the group rate. The deadline to book a room is February 16th. [Sponsorship](#) opportunities are also available. [Contact us](#) with any questions.

(continued on page 6)





INSIDE ABC (continued from page 5)

Save the Date: SMT Journal Club Webinar Set for December 15th

The next ABC Scientific, Medical, and Technical Journal Club Webinar will take place on December 15th at 12 p.m. EST. The webinar is free to all ABC members. An email announcement is forthcoming with additional details including a link to registration and the articles to be reviewed on the webinar. 💧

GLOBAL NEWS

The Official Journal of the European Union recently published “amending Regulation (EC) No. 1907/2006 of the European Parliament and of the Council as regards the substance bis(2-ethylhexyl) phthalate (DEHP) in medical devices.” In the amended regulation, the European Commission (EC) extended the DEHP sunset date per the REACH regulation to July 1st, 2030 instead of May 27th, 2025.

(Source: *Official Journal of the European Union* [Amending Regulation](#), 11/14/23)

The New Zealand Blood Service (NZBS) announced that regulators have lifted the blood donor deferral for variant Creutzfeldt Jakob disease (vCJD). An announcement on the NZBS website stated, “[i]f you lived in the United Kingdom (UK), France or [Ireland] between January 1st, 1980 and December 31st, 1996, for a total period of six months or more, you’ll soon be able to donate blood and plasma in New Zealand. In August 2023, we made a submission to Medsafe, [the New Zealand regulatory authority], recommending the ‘mad cow’ disease (otherwise known as vCJD) restriction be removed. We’re delighted to advise Medsafe have approved our submission. This means we can now get underway with updating our systems and processes and prepare our teams to support this change.”

(Source: NBZS [Announcement](#), 11/14/23)

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Casgevy (exagamglogene autotemcel), a gene therapy for treating sickle cell disease and transfusion-dependent beta thalassemia. According to an agency news release, the therapy “uses the innovative gene-editing tool CRISPR” and the treatment is authorized for use in patients who are 12 years of age and older. The approval is based on results from a, “clinical trial for sickle-cell disease, [in which] 45 patients have currently received Casgevy but only 29 patients have been in the trial long enough to be eligible for the primary efficacy interim analysis. Of these eligible patients, 28 (97 percent) were free of severe pain crises for at least 12 months after treatment. In the clinical trial for transfusion-dependent beta-thalassemia, 54 patients have currently received Casgevy but only 42 patients have been in the trial long enough to be eligible for the primary efficacy interim analysis. Of these, 39 (93 percent) did not need a red blood cell transfusion for at least 12 months after treatment. The remaining three had more than a 70 percent reduction in the need for red cell transfusions. Side effects from treatment were similar to those associated with autologous (from a person’s own cells) stem cell transplants, including (but not limited to) nausea, fatigue, fever, and increased risk of infection. No significant safety concerns were identified during the trials. Safety continues to be closely monitored by the MHRA and the manufacturer.” The newly authorized treatment aims to, “work by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning h[e]moglobin. To do this, stem cells are taken out of bone marrow, edited in a laboratory, and then infused back into the patient after which the results have the potential to be life-long.”

(Source: MHRA [News Release](#), 11/16/23) 💧



COMPANY NEWS

Macopharma has announced that it will no longer use di(2-ethylhexyl) phthalate (DEHP) in any of its products. Caroline Hernu, chief executive officer, explained the company's position in a [video post](#) shared via their [LinkedIn page](#). "Our mission, 'blood is life. We support life,' means a lot to us and we won't compromise on that...[W]e understand our responsibility not only to patients but also to the environment. Despite the fact that DEHP plasticizer has been used in blood bag systems for more than 70 years, DEHP plasticizer has shown toxicity. To protect life, we are removing that substance from all our products. At Macopharma, we have been working for the last 12 years on finding the best alternative to DEHP. We found it so we are not waiting. European authorities plan to ban DEHP from all medical devices by mid-2030...[W]e have decided to start to remove DEHP from all our products in 2024. All our products, everywhere in the world. This is first about safety, but of course we are also committed to ensure the supply of all our customers. By switching very quickly, we are ensuring a safe supply of products to our customers, but also to all patients. All stakeholders must pull together now to achieve this goal."

(Source: Macopharma [Video](#), 10/16/23)

QuidelOrtho Corp. is [reportedly](#) "weighing a sale of its transfusion medicine" business unit according to *Bloomberg*. The article published November 15th noted that the valuation could be between "\$1.5 billion to \$2 billion." An anonymous source in the article also stated that, "[d]eliberations are in the early stages and there's no certainty that QuidelOrtho will decide to proceed with a sale of the unit." The report in *Bloomberg* also explained that, "QuidelOrtho inherited the transfusion medicine business when it acquired Ortho Clinical Diagnostics Holdings Plc in 2022."

(Source: *Bloomberg*, "[QuidelOrtho weighs sale of transfusion medicine unit, sources say](#)," 11/15/23)

Beam Therapeutics has [enrolled](#) the first patient in an open-label, single-arm, multicenter, Phase I/II clinical trial (BEACON) that aims to "evaluate the safety and efficacy" of its investigational gene-edited treatment sickle cell disease (SCD) in adult patients. According to a company news release, "[the investigational treatment is a patient-specific, autologous hematopoietic stem cell (HSC) investigational therapy, which incorporates base edits that are designed to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin. [It] aims to potentially alleviate the effects of mutations causing SCD by leading to increases in fetal hemoglobin (HbF), which inhibits hemoglobin S (HbS) polymerization. Using base editing, a next-generation form of CRISPR, [the investigational gene-edited treatment] in preclinical studies featured high levels of HSC editing (over 90 percent of alleles edited), high and consistent levels of upregulation of HbF (over 60 percent of total hemoglobin), and significant reductions in the disease-causing protein HbS (less than 40 percent of total hemoglobin) – levels that are similar to sickle cell trait carriers, who do not have SCD. Unlike nuclease editors, the BEAM-101 base editor is designed to avoid double stranded breaks during editing, which can result in unwanted chromosomal abnormalities and genotoxic stress."

(Source: Beam Therapeutics [News Release](#), 11/14/23) 💧

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



NEW on CollABORate

COLLABORATE

SHARE STRATEGIC ADVICE | SOLVE CHALLENGES | DEVELOP NEW APPROACHES

Recent discussion topics on the ABC CollABORate Online Member Community include:

- [Blood Typing Donors Prior to Registration](#) (COLLECTIONS & DONOR SERVICES)
- [Type A Liquid Plasma](#) (MEDICAL ISSUES)
- [Cryo Licensure](#) (QUALITY BYTES)
- [Proficiency Testing for Sysmex XN with Blood Bank Module](#) (TECHNICAL DIRECTORS)

ABC members are encouraged to [login](#) and join the conversations today!

Upcoming ABC Webinars & Virtual Events – Don't Miss Out!

- **America's Blood Centers (ABC) QA Education Webinar: QA Back to Basics – Part I** – Dec. 5. More information available to ABC Members, including a link to registration in [MCN 23-097](#).
- **ABC Scientific, Medical, and Technical Journal Club Webinar** – Dec. 15. More information coming soon!



CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2023

Nov. 18-21. **ISBT Regional Congress, Cape Town, South Africa.** [Registration](#) is open. More information available [here](#).

Nov. 29-30. **U.S. Department of Defense Combat Casualty Care Research Program, in conjunction with the Biomedical Advanced Research and Development Authority (BARDA) Radiation/Nuclear Medical Countermeasures Branch, with support from the Medical Technology Enterprise Consortium (MTEC), Blood and Blood Products State of the Technology Meeting, Washington, D.C.** More information available [here](#).

Dec. 5. **America's Blood Centers (ABC) QA Education Webinar: QA Back to Basics – Part I.** [Registration](#) is open. More information including a link to registration is available to ABC members in [MCN 23-097](#).

(continued on page 9)

CALENDAR (continued from page 8)

Dec. 15. **ABC Scientific, Medical, Technical (SMT) Journal Club Webinar.** More information coming soon.

2024

Feb.7-8. **International Plasma and Fractionation Association & EBA Symposium on Plasma Collection and Supply. Leiden, Netherlands.** [Registration](#) is open. More information available [here](#).

Mar. 4-6. **ABC Annual Meeting, Arlington, Va.** [Registration](#) is open. More information available [here](#).

April 12-13. **BEST Meeting, Amsterdam, Netherlands.** More information coming soon.

May 14-16. **2024 ADRP Annual Conference, St. Louis, Mo.** More information available [here](#).

May 15-16. **International Plasma and Fractionation Association/Paul-Ehrlich Institut[e] 30th International Workshop on Surveillance and Screening of Blood-borne Pathogens, Aarhus, Denmark.** More information available [here](#).

Sept. 4-6. **American Society for Clinical Pathology (ASCP), Chicago, Ill.** More information coming soon.

Sept. 30- Oct. 3. **American Association of Tissue Banks (AATB), Denver, Colo.** More information coming soon.

Oct. 19-22. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting, Houston, Texas.** More information coming soon. 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

EQUIPMENT AVAILABLE

For Sale. Spectra Optia – device purchased pre-pandemic and has only had 45 procedures performed on it. Total Run Hours are 181; Current Software Version is 11.3. Optia is in excellent condition and has no known defects. The Blood Bank of Alaska will include a Blood Warmer, as well as cover the cost of shipping. For more information, send inquiries to bbaynard@bbak.org or call (907) 222 – 5664.

For Sale. Two iBF125-GX, i.Series Plasma Upright Freezers. Purchased April of 2023. The freezers were validated in June and have been in use since July. Freezers are in excellent condition and have no known defects. Buyer to cover the cost of shipping. For more information, send inquiries to bbaynard@bbak.org or call (907) 222 – 5664.

POSITIONS

Supply Chain Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference. The Supply Chain Manager at our headquarters location in Gainesville, FL is responsible for vendor selection, negotiation, establishment and maintenance of all purchased materials, supplies, equipment, and services used by the company. The Supply Chain Manager is organized and decisive, and can motivate the team to reach daily and long-range goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

Employee Relations Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management and HR experience, and a passion for making a difference. The Employee Relations Manager at our headquarters location in Gainesville, FL is responsible for facilitating employee relations and resolving personnel issues. The Employee Relations Manager deals with grievances and violations invoking disciplinary action, provides guidance, advice, and support to managers and employees on HR related issues, and oversees the work of eight Human Resources Coordinators.

(continued on page 10)

POSITIONS (continued from page 9)

Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

Immunohematology Reference Lab Manager. LifeSouth Community Blood Centers is seeking an individual who enjoys leading a team of lab professionals dedicated to providing high quality products and services for patients. Our Birmingham, AL IRL is supported by Board Certified Pathologists in Transfusion Medicine, and by LifeSouth's accredited HLA Lab, Molecular Lab, and IRLs in Gainesville, FL and Atlanta, GA. The IRL Manager is responsible for providing onsite day-to-day supervision of testing personnel, ensuring compliance with regulatory agency requirements, and reporting of test results under the direction of the laboratory director. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

Regional Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference in the community. The Regional Manager in The Villages, FL, oversees daily operations of the region, is organized and decisive, and can motivate the team to reach daily and long-range blood collection goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

Chief Operating Officer. Suncoast Blood Centers is seeking a talented and passionate Chief Operating Officer to join their growing team. As a member of the senior leadership team, the Chief Operating Officer plans, organizes, directs, and evaluates all activities associated with the operations of the blood center, including recruitment and retention of donors and sponsor groups, the collection of blood from donors and further manufacturing and distribution of donations in the laboratory. In addition, this executive is accountable for the functions and staff relating to operations planning, contact center, supply chain, research, and continuous process improvement. At SunCoast Blood Center, we lead our teams while keeping our mission, vision, and values at the forefront of all we do. As a leader, you will inspire, train, coach, and collaborate within your department and within the broader organization, with a focus on strategic goal achievement. Suncoast Blood Centers is the only local blood center that has been in the community for over 75 years. Providing blood services to many local hospitals and cancer centers in SWFL. To apply: [Chief Operating Officer - SunCoast Blood Centers](#)

Vice President, Quality & Regulatory Affairs (VPQRA). The Vice President, Quality & Regulatory Affairs (VPQRA) leads the Organization's adherence to regulations and standards established by governing agencies (AABB, FDA, CLIA, State, OSHA, NRC, EU, etc.). Kentucky Blood Center is seeking qualified candidates to fill this key executive leadership role which is responsible for our Quality Assurance (QA) program and regulatory compliance activities. The position has oversight of the QA department and team, and reports to the CEO. Qualifications include MLS/CLS (ASCP) with preference given to candidates with a graduate degree, and blood banking experience. Relocation to the Lexington, Kentucky area required (assistance provided). For more information or to apply, visit <https://www.kyblood-center.org/about-us/careers>

Manager of Donor Services | Manager of Donor Resources | Manager of Hospital Services. The Blood Connection is expanding our operations into Virginia! We are one of the fastest growing blood centers in the country and we are seeking a Manager of Donor Services, a Manager of Donor Resources, and a Manager of Hospital Services who will be responsible for day-to-day operations within each of their respective departments as we expand our services into this new territory. We offer a generous benefits package including a substantial 401k match, 30 days PTO, potential company bonuses, cell phone stipend, and tuition reimbursement. Join our team and help make an impact in your community today. *These roles are based in Roanoke, VA. Prospective candidates may be eligible for relocation assistance.* How to apply: [Manager of Donor Services Application](#) | [Manager of Donor Resources Application](#) | [Manager of Hospital Services Application](#).

Divisional Director. The Blood Connection is expanding our operations into Virginia! We are one of the fastest growing blood centers in the country and we are seeking a Divisional Director who will be responsible for our day-to-day operations and help direct our expansion of services into this new territory. The ideal candidate is a proven and results-focused self-starter with progressive leadership experience and the capacity and drive to help fulfill the needs of our community partners. We offer a generous benefits package including a substantial 401k match, 30 days PTO, potential company bonuses, cell phone stipend, and tuition reimbursement. Join our team and help make an impact in your community today. *Open to candidates residing in localities state-wide. Prospective candidates may be eligible for relocation assistance.* How to apply: [Divisional Director Application](#)

Manager of Technical Services. The Blood Connection is seeking a proactive and results-driven Manager of Technical Services to oversee and manage the daily operations within our technical departments which include

(continued on page 11)

POSITIONS (continued from page 10)

Hospital Services, Biologics Processing, and Reference Laboratory. This position requires an understanding of laboratory operations, including specialist (SBB) skills, and involves supervising staff while performing essential functions within the laboratory. The ideal candidate will hold their SBB and have a background in the Reference Laboratory. We offer a generous benefits package including a substantial 401k match, 30 days PTO, potential company bonuses, cell phone stipend, and tuition reimbursement. Join our team and help make an impact in your community today. *This role is based in Morrisville, NC. Prospective candidates may be eligible for relocation assistance.* How to apply: [Manager of Technical Services Application](#). 💧